Aging is the greatest risk factor for disease

We’re discovering new targets and developing first-in-class therapies for age-related diseases.

Different by design

Like much of the work we do at Calico, our development approach is different by design. Our efforts focus on identifying new targets — that are not currently being pursued by many others — based on our evolving understanding of the biology of aging and age-related diseases.

 

We’re translating that research into first-in-class compounds to target diseases commonly linked with aging with the goal of not only improving life span but also health span.

Calico Stories

Targeting a central stress pathway

What happens when cells fall out of homeostasis due to stress to the system? Human cells have evolved to handle many types of acute stress, but what happens...

Focused on patient benefit

We believe that focusing on new areas of biology and making big leaps in science and then translating these efforts into drug candidates for potential clinical development will lead to patient benefit. Our approach has yielded a portfolio comprised of more than 20 early- and late-stage preclinical compounds in cancer, neurological diseases, and tissue homeostasis and repair.

Born of collaboration and partnership

Our clinical development efforts are buoyed by collaboration, both within Calico and with our external partners. For example, we work closely with the Broad Institute of MIT and Harvard on drug discovery programs, most notably a target screening program that yielded a number of promising immunotherapy cancer targets we are actively pursuing.

 

Another collaboration with AbbVie provides us with the scale and scope necessary to bring a new medicine to patients while maintaining our focus on target discovery and early-stage clinical development. Calico is responsible for preclinical and clinical development through human proof of concept studies, with AbbVie responsible for late stage clinical development and commercialization. Our teams partner hand-in-hand with our colleagues at AbbVie in a collaboration structure that augments the strengths of both partners.